Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
No motivation to move or carry out activities of daily living Joint pain while stationary or in motion Tenderness or tightness in muscles Weaker muscles Reduced flexibility Unable to balance Higher chance of injury These signs and symptoms can be the determining factors for varying health conditions. However, they mainly align with hypomobility.
=== Eddy viscosity === In the study of turbulence in fluids, a common practical strategy is to ignore the small-scale vortices (or eddies) in the motion and to calculate a large-scale motion with an effective viscosity, called the "eddy viscosity", which characterizes the transport and dissipation of energy in the smaller-scale flow (see large eddy simulation). In contrast to the viscosity of the fluid itself, which must be positive by the second law of thermodynamics, the eddy viscosity can be negative.
AAS is calculated as mg of limiting amino acid in 1 g of test protein / mg of same amino acid in 1 g of reference protein. FTPD is calculated as PI - (FP - MFP)/PI. PI is protein intake, FP is fecal protein, MFP is metabolic fecal protein (amount of protein in feces on a protein-free diet). The digestibility test is done with rats. Some sources may list AAS and PD separately as percentages.
The Gulf War was an armed conflict between Iraq and a 42-country coalition led by the United States in response to Saddam Hussein invading neighboring Kuwait on 2 August 1990. The coalition's efforts were in two phases: Operation Desert Shield, which marked the military buildup from August 1990 to January 1991; and Operation Desert Storm, from the bombing campaign against Iraq on 17 January until the American-led liberation of Kuwait on 28 February. The invasion of Kuwait was met with immediate international condemnation. The UN Security Council demanded Iraq's immediate withdrawal and imposed a total embargo on products from Iraq and Kuwait. A coalition began a military buildup in the Persian Gulf region. The broadest military alliance since World War II, its largest contributors were the US, Saudi Arabia, the United Kingdom, and Egypt. The Security Council issued an ultimatum to Iraq on 29 November 1990, expiring on 15 January 1991, to withdraw from Kuwait, with member-states thereafter empowered to use "all necessary means" to force withdrawal. On 17 January, the coalition began aerial and naval bombardment of Iraq and Kuwait, which continued for five weeks. Iraq fired missiles at Israel and at Saudi Arabia, but failed to split Muslim-majority countries from the coalition. On 24 February 1991, the coalition launched a decisive ground assault liberating Kuwait and promptly advancing into Iraqi territory. The coalition halted its ground advance after one hundred hours, and declared a ceasefire.
The sandwich or indirect ELISA provides a solution to this problem by using a "capture" antibody specific for the test antigen to pull it out of the serum's molecular mixture. ELISA may be run in a qualitative or quantitative format. Qualitative results provide a simple positive or negative result (yes or no) for a sample. The cutoff between positive and negative is determined by the analyst and may be statistical. Two or three times the standard deviation (error inherent in a test) is often used to distinguish positive from negative samples. In quantitative ELISA, the optical density (OD) of the sample is compared to a standard curve, which is typically a serial dilution of a known-concentration solution of the target molecule. For example, if a test sample returns an OD of 1.0, the point on the standard curve that gave OD = 1.0 must be of the same analyte concentration as the sample. The use and meaning of the names "indirect ELISA" and "direct ELISA" differ in the literature and on websites depending on the context of the experiment. When the presence of an antigen is analyzed, the name "direct ELISA" refers to an ELISA in which only a labeled primary antibody is used, and the term "indirect ELISA" refers to an ELISA in which the antigen is bound by the primary antibody which then is detected by a labeled secondary antibody. In the latter case, a sandwich ELISA is clearly distinct from an indirect ELISA. When the "primary" antibody is of interest, e.g.
Sources: en.wikipedia.org
Affinity monolith chromatography provides another approach to drug response measurements. David Hage at the University of Nebraska–Lincoln binds ligands to monolithic supports and measures the equilibrium phenomena of binding interactions between drugs and serum proteins. A monolith-based approach at the University of Bologna, Italy, is currently in use for high-speed screening of drug candidates in the treatment of Alzheimer's. In 2003, Regnier and Liu of Purdue University described a multi-dimensional LC procedure for identifying single nucleotide polymorphisms (SNPs) in proteins. SNPs are alterations in the genetic code that can sometimes cause changes in protein conformation, as is the case with sickle cell anemia. Monoliths are particularly useful in these kinds of separations because of their superior mass transport capabilities, low backpressures coupled with faster flow rates, and relative ease of modification of the support surface. Bioseparations on a production scale are enhanced by monolith column technologies as well. The fast separations and high resolving power of monoliths for large molecules means that real-time analysis on production fermentors is possible.Fermentation is well known for its use in making alcoholic beverages, but is also an essential step in the production of vaccines for rabies and other viruses. Real-time, on-line analysis is critical for monitoring of production conditions, and adjustments can be made if necessary.
Narrated by Alun Lewis, directed by Gary Leach, produced by Geoff Deehan, produced by Sandlin Productions 24 November The Dyslexic Engineer, about Ben Bowlby, born on 2 November 1966; his VS91 car at Snetterton Circuit, with a Vauxhall Astra engine, with footage mostly from the end of the earlier documentary in September 1990; his studies at the Polytechnic of East London; Richard Bowlby, his father from Hampstead, who also realised that he was dyslexic; Rosalind Rathouse, his former remedial teacher; Roy Greenfield, a retired maths teacher from King Alfred School, London, who believed that perhaps people would adapt to mathematics more if the subject was taught later in life, as people are often put off the subject at secondary school; Ben gained nine O-levels but couldn't acquire Mathematics A-level above grade E after, two attempts; Xenia Bowlby; his polytechnic course tutor, Alan Slawson, and limited-slip differentials; his car raced in the Clubman (racing car class); he was sponsored by Ripspeed clothing and Spax Performance shock absorbers; Eric Broadly of Lola Cars; he joined Lola Cars in October 1991; he had attempted to gain a place at Lancaster University to study Engineering; Mike Blanchet of Lola Cars; empirical research in designing and building motor racing cars; Mark Williams, head of Formula 3000 at Lola Cars. Narrated by Ian Holm, produced by Michael Proudfoot, directed by Patrick Uden, made by Uden Associates.
In 1970, she began research at the Indian Institute of Technology, Kanpur (IIT Kanpur). In that year, she married Subramania Ranganathan, with whom she would go on to author Challenging problems in organic reaction mechanisms (1972), Art in biosynthesis: the synthetic chemist's challenge (1976), and Further challenging problems in organic reaction mechanisms (1980)—as well as editing an ongoing series titled "Current Organic Chemistry Highlights". She continued her research at IIT Kanpur on the basis of fellowships. Unwritten rules prevented her from joining the faculty because her husband was already a member. She began work at Regional Research Laboratory, Trivandrum in 1993, and at IICT, Hyderabad in 1998., where she became Deputy Director. During these years, she conducted ongoing collaborations with Isabella Karle at the U.S. Naval Research Laboratory. Darshan Ranganathan was diagnosed with breast cancer in 1997, and died on her 60th birthday, in 2001. The biennial "Professor Darshan Ranganathan Memorial Lecture", which is to be "delivered by a woman scientist who has made outstanding contributions in any field of Science and Technology" was established in her memory by her husband, in 2001.
== Etymology == The term parenchyma is Neo-Latin from the Ancient Greek word παρέγχυμα parenchyma meaning 'visceral flesh', and from παρεγχεῖν parenkhein meaning 'to pour in' from παρα- para- 'beside' + ἐν en- 'in' + χεῖν khein 'to pour'. Originally, Erasistratus and other anatomists used it for certain human tissues. Later, it was also applied to plant tissues by Nehemiah Grew.
=== Trauma === The bony area that makes up the human eye socket provides exceptional protection to the sclera. However, if the sclera is ruptured by a blunt force or is penetrated by a sharp object, the recovery of full former vision is usually rare. If pressure is applied slowly, the eye is actually very elastic. However, most ruptures involve objects moving at some velocity. The cushion of orbital fat protects the sclera from head-on blunt forces, but damage from oblique forces striking the eye from the side is not prevented by this cushion. Hemorrhaging and a dramatic drop in intraocular pressure are common, along with a reduction in visual perception to only broad hand movements and the presence or absence of light. However, a low-velocity injury which does not puncture and penetrate the sclera requires only superficial treatment and the removal of the object. Sufficiently small objects which become embedded and which are subsequently left untreated may eventually become surrounded by a benign cyst, causing no other damage or discomfort.
Sources: en.wikipedia.org
Causes disease clinically similar to types II and III, thought to be related to inability of chaperone protein HP47 to unbind from collagen type I, as to do so it needs to bind to the missing ER lumen protein retaining receptor 2 protein encoded by KDELR2. Given the rapid rate of type discovery, it is extremely likely that there are other genes associated with OI that have yet to be reported.
Fumito Ueda (上田 文人, Ueda Fumito; born April 19, 1970) is a Japanese video game designer, game director and visual artist. Ueda is best known as the director and lead designer of Ico (2001) and Shadow of the Colossus (2005) during his tenure at Sony Computer Entertainment's Japan Studio, and The Last Guardian (2016) through his own development company GenDesign. His games have achieved cult status and are distinguished by their usage of minimal plot and scenario using fictional languages, and use of overexposed, desaturated light. He has been described by some as an auteur.
In November 2023, the first global AI Safety Summit was held in Bletchley Park in the UK to discuss the near and far term risks of AI and the possibility of mandatory and voluntary regulatory frameworks. 28 countries including the United States, China, and the European Union issued a declaration at the start of the summit, calling for international co-operation to manage the challenges and risks of artificial intelligence. In May 2024 at the AI Seoul Summit, 16 global AI tech companies agreed to safety commitments on the development of AI. In March 2026, the United Nations convened the inaugural meeting of the Independent International Scientific Panel on AI, a 40-member expert body established under the Global Digital Compact to produce annual evidence-based reports on AI's societal impacts.
== Contributions == While still a student, Knudsen worked at Novo Nordisk, initially working on laundry detergent enzymes. Alongside fellow student Shamkant Patkar, she discovered an enzyme capable of removing microscopic strands of cotton that pill up on clothing from repeated wear. After this project, Knudsen joined full-time as part of a research group at Novo Nordisk that aimed to identify new treatments for diabetes, by developing small molecule drugs targeting specific metabolic pathways. One project revolved around glucagon-like peptide-1 (GLP-1), a hormone that stimulates the production of insulin but has a short half-life of minutes in the body. GLP-1 had been previously identified by researchers such as Jens Juul Holst in Denmark, who joined Novo Nordisk as a consultant, and Joel Habener, Daniel J. Drucker, and Svetlana Mojsov at Massachusetts General Hospital. Knudsen's team screened numerous chemical compounds to identify whether they could bind to the GLP-1 receptor sufficiently to stimulate insulin secretion. Eventually, they developed a new compound called liraglutide, which is an agonist for the GLP-1 receptor. It is a chemical analogue of GLP-1, with a fatty acid and spacer attached. These modifications increased its ability to dissolve in water and bind to albumin, which increase its bioavailability—its lifetime in the bloodstream, and so the duration of its action in the body. Liraglutide was approved as a treatment for diabetes under the brand name Victoza in the United States in 2010.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.